PMID- 30276363
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2589-0514 (Electronic)
IS  - 2095-882X (Print)
IS  - 2095-882X (Linking)
VI  - 4
IP  - 3
DP  - 2018 Sep
TI  - Progress in targeted therapy for breast cancer.
PG  - 164-175
LID - 10.1016/j.cdtm.2018.04.002 [doi]
AB  - Breast cancer is a multistep, multifactorial, and heterogeneous disease. 
      Significant transformations have occurred in the systemic management of breast 
      cancer in the past decade. Due to the further understanding of pathogenesis, 
      scientists have found plenty of signaling pathways and correspondingly 
      therapeutic targets in breast cancer, such as hormone receptor, human epidermal 
      growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), 
      vascular endothelial growth factor (VEGF), phosphoinositide-3-kinase (PI3K), 
      v-akt murine thymoma viral oncogene homolog (AKT), mechanistic target of 
      rapamycin (mTOR), cyclin-dependent kinase 4/6 (CDK4/6), poly (adenosine 
      diphosphate-ribose) polymerase (PARP), and programmed death-1 (PD-1). Targeted 
      therapy, which optimizes the accuracy of antitumor activity and minimizes 
      toxicity to normal tissues, plays a crucial role in breast cancer treatment in 
      the era of precision medicine. In this review, we aimed to summarize the latest 
      developments in targeted therapy for breast cancer and discuss the existing 
      problems.
FAU - Ju, Jie
AU  - Ju J
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Beijing 100021, China.
FAU - Zhu, An-Jie
AU  - Zhu AJ
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Beijing 100021, China.
FAU - Yuan, Peng
AU  - Yuan P
AD  - Department of VIP Medical Services, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing 100021, China.
LA  - eng
PT  - Journal Article
DEP - 20180707
PL  - United States
TA  - Chronic Dis Transl Med
JT  - Chronic diseases and translational medicine
JID - 101679934
PMC - PMC6160667
OTO - NOTNLM
OT  - Breast cancer
OT  - Precision medicine
OT  - Targeted therapy
EDAT- 2018/10/03 06:00
MHDA- 2018/10/03 06:01
PMCR- 2018/07/07
CRDT- 2018/10/03 06:00
PHST- 2018/01/18 00:00 [received]
PHST- 2018/10/03 06:00 [entrez]
PHST- 2018/10/03 06:00 [pubmed]
PHST- 2018/10/03 06:01 [medline]
PHST- 2018/07/07 00:00 [pmc-release]
AID - S2095-882X(18)30006-9 [pii]
AID - 10.1016/j.cdtm.2018.04.002 [doi]
PST - epublish
SO  - Chronic Dis Transl Med. 2018 Jul 7;4(3):164-175. doi: 10.1016/j.cdtm.2018.04.002. 
      eCollection 2018 Sep.